Business Context and Reporting Period
This Form 8-K, filed on October 28, 2013, by Crane Co. (not Crane NXT, Co.), reports the results of operations for the quarter ended September 30, 2013. The filing primarily details the Company's ongoing asbestos liability exposure, claim activity, and financial estimates related to tort system litigation.
Key Financial Metrics: Asbestos Liability and Costs
The filing provides specific data regarding asbestos-related costs and liabilities, though it does not contain general revenue, profit, or cash flow figures for the Company's core operations (referenced in Exhibits 99.1 and 99.2).
- Total Asbestos Liability: $724 million as of September 30, 2013 (down from $894 million recorded as of December 31, 2011).
- Current Portion of Liability: $92 million (estimated costs to be paid within the next 12 months).
- Insurance Receivable Asset: $182 million as of September 30, 2013 (representing probable reimbursements).
- Cumulative Resolved Claims: Approximately 95,000 claims resolved (excluding MARDOC claims) with a total settlement cost of approximately $390 million.
- Average Settlement Cost: Approximately $4,100 per resolved claim cumulatively.
Asbestos Costs Incurred vs. Cash Payments (Nine Months Ended Sept 30, 2013)
| Item | 2013 (in millions) | 2012 (in millions) |
|---|---|---|
| Total Costs Incurred (Settlement + Defense) | $67.9 | $73.5 |
| Pre-tax Cash Payments (Net of Insurance) | $48.3 | $60.1 |
| Settlement/Indemnity Costs Incurred | $23.2 | $29.3 |
| Defense Costs Incurred | $44.7 | $44.2 |
Material Changes and Claim Activity
As of September 30, 2013, the Company had 53,822 pending asbestos claims, a decrease from 56,773 in the prior year period. The filing details significant legal developments:
- Claim Volume: New claims filed in the nine months ended September 30, 2013, totaled 2,207, compared to 2,720 in the same period in 2012.
- Dismissals: Dismissals increased to 4,139 in the nine-month period of 2013, compared to 3,983 in 2012.
- Recent Verdicts: Several adverse jury verdicts were reported in 2013, including a $35 million verdict in the Ivo Peraica claim (NY), an $11 million compensatory and $11 million exemplary verdict in the Lloyd Garvin claim (SC), and a $3.1 million verdict in the Lee Holdsworth claim (NY). The Company is pursuing post-trial motions and appeals in these matters.
- Liability Estimate Stability: Management determined no change to the liability estimate was warranted for the period ended September 30, 2013, as actual experience approximated assumptions.
Outlook, Risks, and Management Commentary
Management utilizes a forecast period extending through 2021 for estimating asbestos liabilities, based on the stabilization of mesothelioma claims and favorable case law trends. The Company does not believe it can reasonably estimate costs beyond 2021.
- Forecast Period: The liability estimate covers claims filed or projected to be filed through 2021. Approximately 80% of the liability is attributable to future claims.
- Insurance Coverage: The Company has "coverage-in-place" agreements with 11 excess insurer groups and policy buyout agreements totaling $82.5 million. The estimated insurance recovery rate remains at approximately 25% of the liability.
- Risks and Uncertainties: Significant uncertainties remain regarding the number of future claims, settlement costs, and defense costs. Factors such as legislative changes, bankruptcy filings of other defendants, and appellate rulings could materially alter the liability estimate.
- Cash Flow Timing: Cash payments generally lag the recognition of costs by several months due to the timing of releases and insurer reimbursement practices.
Investor Verification Checklist
- Verify the full quarterly financial results (Revenue, Net Income, EPS) in the referenced Exhibits 99.1 and 99.2, as this 8-K focuses solely on asbestos liabilities.
- Monitor the status of the Ivo Peraica ($35M), Lloyd Garvin ($22M total), and Lee Holdsworth ($3.1M) verdicts, as post-trial motions and appeals are pending.
- Review the trend of new mesothelioma claims versus dismissals to assess the stability of the 2021 forecast period.
- Confirm the status of the single remaining solvent excess insurer that has not entered into a coverage-in-place agreement.
- Assess the impact of the $92 million current liability portion on the Company's short-term liquidity.